

1/76

FIG. 1A





FIG. 1B



2/76

FIG. 2A




FIG. 2B




FIG. 3A





FIG. 3B



4/76

FIG. 4A





FIG. 4B



5/76

FIG. 5A




FIG. 5B




FIG. 6A




FIG. 6B




FIG. 7B




FIG. 7A




FIG. 8A




FIG. 8B




FIG. 9A

EGFRt selection marker




FIG. 9B
EGFRt Suicide switch




FIG. 10A




FIG. 10B





FIG. 10C



12/76

FIG. 11A




FIG. 11B

CD8a Hinge/Tm + <u>TEV Cut</u> + ER Tag	Construct	ER protein motif	Size (AA)	Source
	487	adenovirus E3-19K protein	95	Viral
	488	engineered E3-19K 1	95	Viral
	489	engineered E3-19K 2	96	Viral
	490	engineered E3-19K 3	98	Viral
	491	KDEL R2 cytoplasmic	91	Human
	492	carboxypeptidase D (CPD)	132	Human
	493	DEGRON + adenovirus E3-19K retention motif	137	Viral
	494	Coronavirus infectious bronchitis virus (IBV) S protein ER motif	105	Viral
	495	HCV NS3 helix	134	Viral
	496	HCV helicase domain	145	Viral

FIG. 12A




FIG. 13A




FIG. 13B




FIG. 13C




FIG. 13D




FIG. 13E




FIG. 14A




FIG. 14B




FIG. 15A




FIG. 15B





FIG. 15C



24/76

FIG. 15D




FIG. 15E




FIG. 16A





FIG. 16B



27/76

FIG. 17A




FIG. 17B




FIG. 18A




FIG. 18B




FIG. 19A





FIG. 19B



30/76

FIG. 20A




FIG. 20B




FIG. 20C

Pre-enriched (triple positive=16.7%)




FIG. 20D

Post-enriched (triple positive=92.1%)




FIG. 21B

EGFRt-STASH variant 493 with PuroR




FIG. 21A

EGFRt-STASH variant 493




FIG. 22A




FIG. 22B




FIG. 22C




FIG. 24




FIG. 23




FIG. 26




FIG. 25




FIG. 27




FIG. 28




Figure 2




FIG. 30




FIG. 31




FIG. 32






FIG. 33



45/76

FIG. 34






FIG. 36




FIG. 37




FIG. 38




FIG. 39A





FIG. 39B







FIG. 40B






FIG. 41A

55/76

FIG. 41B




FIG. 42A

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: BFP and GFP expression




FIG. 42B

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: BFP and GFP expression




FIG. 42C

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: BFP and GFP expression




FIG. 42D

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: BFP and GFP expression




FIG. 43A

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: surface EGFR expression




FIG. 43B

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: surface EGFR expression




FIG. 43C

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: surface EGFR expression




FIG. 43D

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: surface EGFR expression




FIG. 43E

Viral supernatant dilutions of EGFR STASH 501 and TEV protease 413: surface EGFR expression




FIG. 44

Surface EGFR expression with protease 797, a minimized protease construct with a 501 ER retention tag




FIG. 45A

Identification of human protease for use with STASH select




FIG. 45A (Cont.)




FIG. 45A (Cont.)




FIG. 45A (Cont.)





FIG. 45A (Cont.)



71/76

FIG. 45B

Tube	Protease	Cleavage site
53	821	834
54	821	835
55	822	836
56	823	837
57	821	501
58	823	501
59	823	838
60		839
61		840
62	824	838
63		839
64		840
65	821	838
66		839
67		840
68	822	838
69		839
70		840
71	825	838
72		839
73		840
74	826	838
75		839
76		840
77	827	838
78		839
79		840
80	828	838
81		839
82		840

FIG. 45C

#	Protease
821	KLK3
822	KLK4
823	KLK6
824	KLK8
825	KLK11
826	KLK13
827	KLK14
828	KLK15

FIG. 45D

#	CS sequence
834	KLFSSKQ
835	GISSFYSSTEERLW
836	AAPR
837	WEAVRYSAMW
838	VPR
839	IEGR
840	YASR

72/76

FIG. 46A

Two-way STASH Select using a combination of CRISPR knock-in and retroviral gene delivery methods





FIG. 46B

Two-way STASH Select using a combination of CRISPR knock-in and retroviral gene delivery methods



73/76

FIG. 46C

Two-way STASH Select using a combination of CRISPR knock-in
and retroviral gene delivery methods




FIG. 47A

Two-way STASH Select with various EGFR truncations




FIG. 47B

Two-way STASH Select with various EGFR truncations




FIG. 47C

Two-way STASH Select with various EGFR truncations

